Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. Among authors: raymond e. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E, ten Bokkel Huinink WW, Taïeb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH; European Organization for the Research and Treatment of Cancer Early Clinical Study Group. Raymond E, et al. J Clin Oncol. 2002 Aug 15;20(16):3508-21. doi: 10.1200/JCO.2002.09.030. J Clin Oncol. 2002. PMID: 12177112 Clinical Trial.
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
van Kesteren C, Mathôt RA, Raymond E, Armand JP, Fumoleau P, Punt C, Ravic M, Wanders J, Beijnen JH, Schellens JH; Early Clinical Studies Group of the EORTC and NDDO Oncology. van Kesteren C, et al. Among authors: raymond e. Br J Clin Pharmacol. 2002 Nov;54(5):463-71. doi: 10.1046/j.1365-2125.2002.01684.x. Br J Clin Pharmacol. 2002. PMID: 12445024 Free PMC article. Clinical Trial.
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH. van Kesteren C, et al. Among authors: raymond e. Invest New Drugs. 2005 Jun;23(3):225-34. doi: 10.1007/s10637-005-6730-3. Invest New Drugs. 2005. PMID: 15868378
596 results